Latest Regulatory Compliance News

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

BPM Minerals has completed its first reverse circulation drilling at the high-grade Beachcomber Prospect, confirming a major gold system across a 75 km corridor and securing $3.5 million to fuel expanded 2026 exploration.

Yari Minerals has appointed seasoned coal geologist Courtney Taylor as Executive Director and incoming Managing Director to spearhead the Rolleston South Coal Project’s next phase. This leadership change marks a strategic pivot as the company prepares for feasibility studies.

Banco Santander has launched A$550 million of fixed rate senior notes due in 2031, exclusively aimed at professional and eligible counterparties under MiFID II regulations. The notes will be listed on the ASX and carry investment-grade ratings.

Banco Santander has launched a A$450 million tranche of floating rate senior notes due in 2031, targeting exclusively professional and eligible counterparties under MiFID II regulations. The notes offer a quarterly interest rate tied to the 3-month BBSW plus a margin of 0.97%.

Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.

Finder Energy has completed a $5.2 million capital raise through a share placement to its directors and substantial shareholder Longreach Capital, following shareholder approval.

Alice Queen Limited (AQX) has been suspended from ASX quotation due to its failure to adequately respond to regulatory queries, raising questions about its compliance status and future trading prospects.

Askari Metals has responded to an ASX query regarding an inadvertent breach of Listing Rule 10.11 after issuing securities to a related party without prior shareholder approval during a recent rights issue. The company outlines the circumstances and its planned remedial actions.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.